GEMCITABINE (GEM) AND CISPLATIN (CIS) IN ADVANCED-METASTATIC TRANSITIONAL CELL CARCINOMA (TCC) OF BLADDER: A PHASE II STUDY
Adamo V.,D'Angelo,Ferraro G.,Altavilla G.,Alafaci E.,Garipoli C.,Magno C.,Scimone A,Zanghì M.
25TH Esmo Congress –Hamburg , Germany 2000
– A PHASE II STUDY (21 DAY REGIMEN) OF GEM CITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER
Adamo V.,Scimone A.,De Vincenzo F.,D'Angelo A.,Ferraro G.,Altavilla G.,Garipoli C.,Sergi C.,Zanghì M.
Third National Congress of Medical Oncology 4-7 Novembre 2001- Napoli
- GEMCYTABINE AND PEGYLATE LIPOSOMAL DOXORUBICIN IN RECURRENT EPITHELIAL OVARIAN CANCER (REOC). PRELIMINARY REPORT OF A PHASE II STUDY.
Zanghì M,Adamo V.,De Vincenzo F.,Garipoli C.,Alafaci E.,Maisano C.,Scimone A.
4TH National Congress of Medical Oncology 28 Sept-1 Oct ,2002 -Torino
– EPIRUBICIN AND PACLITAXEL IN ADVANCED BREST CANCER : A PHASE II STUDY
Garipoli C.,Adamo V.,Rossello R.,Zanghì M.,Alafaci E.,Altavilla G.,Maisano C.,Spitaleri G.
4TH National Congress of Medical Oncology 28 Sept-1 Oct ,2002 -Torino
– SECOND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): OUR EXPERIENCE.
Alafaci E.,Rossello R.,De Vincenzo F.,Maisano C.,Ferraro G.,Garipoli C.,Zanghì M.,Sergi C.,Adamo V.
5TH National Congress of Medical Oncology 21-24 October 2003 -Roma
– ZD 1839 “IRESSA” IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC): ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT.
Adamo V.,Scimone A.,Spitaleri G.,Alafaci E.,Altavilla G.,Ferraro G.,Garipoli C.,Maisano C.,Zanghì M.
5TH National Congress of Medical Oncology 21-24 October 2003 -Roma
- PHASE II STUDY OF LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN THE TREATMENT OF RECURRENT OVARIAN CANCER.
Ferrandina G.,Paris I.,D'Agostino G.,Lorusso D.,Zanghì M.,Scandurra G.,Pisconti S.,Adamo V. Scambia G.
6TH National Congress of Medical Oncology 21-24 September 2004 – Bologna
- PHASE II TRIAL ZD1839 ( IRESSA) SECOND-THIRD LINE IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:PRELIMINARY RESULTS.
27TH Esmo Congress 2004- Vienna
- THE RELATIONSHIP BETWEEN THE AROUND-THE-CLOCK OPIOID REGIMEN AND THE EFFECTIVE DOSE OF ORAL TRANSMUCOSAL FENTANYL CITRATE (OFTC): A NEW METHOD FOR DOSE TITRATION.
Ferraro G.,Scandurra G.,Rossello R.,Alafaci E.,Zanghì M.,Montalto E.,Iorfida M.,Adamo V.
Ann. Oncol. Suppl 7 - 8th National GOIM Congress 18-21 June 2006 Messina
-SAFETY OF ZOLEDRONIC ACID IN BONE METASTATIC BREAST CANCER PATIENTS: A RETROSPECTIVE ANALYSIS.
Ferraro G.,Caristi N.,Maugeri Saccà M.,Arcanà C.,Adamo B.,Briguglio R.,Zanghì M.,Adamo V.
Ann. Oncol. Suppl 11- 9th National Congress of Medical Oncology 12-15 October 2007 Palermo
38) -OVERVIEW AND NEW STRATEGIES IN METASTATIC BREAST CANCER (MBC) FOR TREATMENT OF TAMOXIFEN RESISTANCE PATIENTS.(Symposium article)
Adamo V.,Iorfida M.,Montalto E.,Festa V.,Garipoli C.,Scimone A.,Zanghì M.,Caristi N.
annals of Oncology Vol. 18 Suppl.6 European Society of Medical Oncology 2007
– safety of trastuzumab-containing therapies in elderly women with metaSTATIC breast cancer.
Ferraro G.,Rossello R.,Ricciardi G.,Adamo B.,Garipoli C.,Zanghì M.,Arcanà C.,Briguglio R.,Mesiti M.,Adamo V.
annals of Oncology Vol. 20 Suppl. 8-10th National Congress of Medical Oncology- Ottobre 2009